Bufexamac
File:Bufexamac.png | |
Systematic (IUPAC) name | |
---|---|
2-(4-butoxyphenyl)-N-hydroxyacetamide | |
Clinical data | |
Routes of administration | Topical, rectal |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Excretion | Renal |
Identifiers | |
CAS Number | 2438-72-4 |
ATC code | M01AB17 (WHO) M02AA09 |
PubChem | CID 2466 |
Chemical data | |
Formula | C12H17NO3 |
Molar mass | 223.268 g/mol[[Script error: No such module "String".]] |
Script error: No such module "collapsible list". |
Bufexamac is a drug used as an anti-inflamatory agent on the skin, as well as rectally. Common brand names include Paraderm and Parfenac.
Contents
[hide]Indications
Ointments and lotions containing bufexamac are used for the treatment of subacute and chronic eczema of the skin, including atopic eczema, as well as sunburn and other minor burns[citation needed], and itching. Suppositories containing bufexamac in combination with local anaesthetics are used against haemorrhoids.[1]
Pharmacology
Bufexamac is thought to act by inhibiting the enzyme cyclooxygenase, which would make it an non-steroidal anti-inflammatory drug. Evidence on the mechanism of action is scarce.[2]
Side-effects
Bufexamac can cause severe contact dermatitis which is often hard to distinguish from the initial condition.[3] As a consequence, the European Medicines Agency recommended to withdraw the marketing approval in April 2010.[4]
References
Cite error: Invalid <references>
tag;
parameter "group" is allowed only.
<references />
, or <references group="..." />
- Jump up ↑ Dinnendahl, V, Fricke, U, ed. (2010). Arzneistoff-Profile (in German) (23 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. ISBN 978-3-7741-98-46-3. Text "volume2" ignored (help)
- Jump up ↑ Gloor, Max; Thoma, Karl; Fluhr, Joachim (2000). Dermatologische Externatherapie: Unter besonderer Berücksichtigung der Magistralrezeptur (in German). Springer. p. 349. ISBN 3540671749.
- Jump up ↑ "Bufexamac: Ein Ekzemtherapeutikum, das selbst häufig allergische Kontaktekzeme hervorruft". Deutsches Ärzteblatt (in German) (47). 2000.
- Jump up ↑ "European Medicines Agency recommends revocation of marketing authorisations for bufexamac" (PDF). European Medicines Agency. 22-04-2010. Check date values in:
|date=
(help)
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- All articles with unsourced statements
- Articles with unsourced statements from May 2010
- Articles with invalid date parameter in template
- 2Fix
- Anti-inflammatory agents
- Hydroxamic acids
- Phenol ethers
- Pages with citations using unnamed parameters
- CS1 maint: Multiple names: editors list
- CS1 maint: Unrecognized language
- CS1 errors: dates